Sartorius AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SARTF research report →
About the company
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently.
- CEO
- Michael Grosse
- IPO
- 2010
- Employees
- 13,985
- HQ
- Goettingen, NI, DE
Price Chart
- Market Cap
- $14.69B
- P/E
- 96.43
- P/S
- 4.40
- P/B
- 5.74
- EV/EBITDA
- 19.43
- Div Yield
- 0.33%
- Gross Margin
- 45.59%
- Op Margin
- 16.52%
- Net Margin
- 4.58%
- ROE
- 6.05%
- ROIC
- 4.61%
- Revenue
- $3.54B · 4.62%
- Net Income
- $154.84M · 84.34%
- EPS
- $2.25 · 84.43%
- Op Income
- $651.16M
- FCF YoY
- -62.21%
- 52W High
- $227.00
- 52W Low
- $181.58
- 50D MA
- $212.85
- 200D MA
- $217.41
- Beta
- 1.47
- Avg Volume
- 35
Get TickerSpark's AI analysis on SARTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SARTF coverage
Recent articles, reports, and earnings notes.
No research on SARTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SARTF report →Similar companies
Peers in the same neighborhood.